Diabetes,a prevalent chronic metabolic disorder,often leads to severe complications.Currently,existing treatment methods may pose life-threatening risks due to poor patient compliance and inaccurate dosing of subcutan...Diabetes,a prevalent chronic metabolic disorder,often leads to severe complications.Currently,existing treatment methods may pose life-threatening risks due to poor patient compliance and inaccurate dosing of subcutaneous insulin injections.Hence,a biomimetic red blood cell(RBC)membrane-coated glucose-responsive nanoplatform is developed for controlling insulin release.Functionalizing nanoplatforms with RBC membrane can prolong the half-life of nano-formulation in vivo mediated by the biomimetic immune escape.Simultaneously,the cascade catalytic effect of glucose oxidase(GOx)encapsulated in metal-organic frameworks(MOFs)and hemoglobin(Hb)in the RBC membrane are able to not only facilitate glucose-responsive insulin release,but also eliminate the detrimental by-product hydrogen peroxide(H_(2)O_(2))resulting from the Hb mediated H_(2)O_(2)scavenging.Both in vitro and in vivo studies have demonstrated the favorable glucose-responsive performances of this advanced nano-platform with a single intravenous injection maintaining blood glucose balance in Type 1 Diabetes(T1D)mice for an extended duration without the hypoglycemia risk.Therefore,this biomimetic insulin delivery system is poised to function as a strategy for the intravenous insulin administration,offering a promising drug candidate for the self-adaptive long-term T1D treatment.展开更多
基金National Natural Science Foundation of China(Nos.32171324 and 31971301)helped to support this work,Fundamental Research Funds for Central Universities(Nos.2024CDJXY017 and 2023CDJXY-051)Fundamental Research Funds for the National Key R&D Project(No.2022YFF0710700)+1 种基金2030 Major Research Projects for Technological Innovation(No.2023ZD0509402)Natural Science Foundation of Chongqing(Nos.2022NSCQ-BHX4850,CSTB2022NSCQ-BHX0718,and CSTB2022NSCQ-BHX0724).
文摘Diabetes,a prevalent chronic metabolic disorder,often leads to severe complications.Currently,existing treatment methods may pose life-threatening risks due to poor patient compliance and inaccurate dosing of subcutaneous insulin injections.Hence,a biomimetic red blood cell(RBC)membrane-coated glucose-responsive nanoplatform is developed for controlling insulin release.Functionalizing nanoplatforms with RBC membrane can prolong the half-life of nano-formulation in vivo mediated by the biomimetic immune escape.Simultaneously,the cascade catalytic effect of glucose oxidase(GOx)encapsulated in metal-organic frameworks(MOFs)and hemoglobin(Hb)in the RBC membrane are able to not only facilitate glucose-responsive insulin release,but also eliminate the detrimental by-product hydrogen peroxide(H_(2)O_(2))resulting from the Hb mediated H_(2)O_(2)scavenging.Both in vitro and in vivo studies have demonstrated the favorable glucose-responsive performances of this advanced nano-platform with a single intravenous injection maintaining blood glucose balance in Type 1 Diabetes(T1D)mice for an extended duration without the hypoglycemia risk.Therefore,this biomimetic insulin delivery system is poised to function as a strategy for the intravenous insulin administration,offering a promising drug candidate for the self-adaptive long-term T1D treatment.
